<DOC>
	<DOCNO>NCT02715804</DOCNO>
	<brief_summary>The purpose study compare efficacy safety PEGylated Recombinant Human Hyaluronidase ( PEGPH20 ) combine nab-paclitaxel plus gemcitabine ( PAG treatment ) , compare placebo combine nab-paclitaxel plus gemcitabine ( AG treatment ) , participant hyaluronan ( HA ) -high Stage IV previously untreated pancreatic ductal adenocarcinoma ( PDA ) . Participants randomize 2:1 ratio PAG AG treatment .</brief_summary>
	<brief_title>A Study PEGylated Recombinant Human Hyaluronidase Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel Gemcitabine Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<criteria>1 . Signed , write Institutional Review Board/Ethics Committeeapproved Informed Consent Form ( ICF ) . 2 . Stage IV pancreatic ductal adenocarcinoma ( PDA ) histological confirmation PDA via archive fresh core biopsy either primary tumor 1 metastatic site . 3 . Participants must determine hyaluronanhigh base tumor biopsy meet requirement note previous inclusion criterion . 4 . At least 1 tumor metastasis measurable compute tomography ( CT ) scan per Response Evaluation Criteria Solid Tumors ( RECIST ) version 1.1 criterion , exclude primary pancreatic lesion . 5 . If participant adjuvant therapy ( chemotherapy nonmetastatic pancreatic cancer combination without radiation therapy ) , tumor recurrence disease progression must occur sooner 6 month complete last dose adjuvant therapy , provide toxicity return baseline â‰¤ Grade 1 . 6 . Eastern Cooperative Oncology Group Performance Status 0 1 . Exclusion criterion : 1 . Clinical evidence deep vein thrombosis ( DVT ) , pulmonary embolism ( PE ) know thromboembolic ( TE ) event present screening period . 2 . Previous radiotherapy , surgery , chemotherapy , investigational therapy treatment metastatic disease . a. Palliative radiotherapy pain control metastatic bone lesion allow . 3 . Known central nervous system involvement brain metastasis . 4 . New York Heart Association Class III IV cardiac disease myocardial infarction within past 12 month . 5 . History cerebrovascular accident transient ischemic attack . 6 . Preexisting carotid artery disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Pancreatic ductal adenocarcinoma ( PDA )</keyword>
	<keyword>Pancreatic ductal carcinoma</keyword>
	<keyword>PEGylated Recombinant Human Hyaluronidase ( PEGPH20 )</keyword>
	<keyword>Nab-paclitaxel</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Stage IV</keyword>
</DOC>